**This commentary refers to 'Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials' by Y. Ahmad *et al*., doi:10.1093/eurheartj/ehaa135.**

A recent systematic review and meta-analysis study was published in the *European Heart Journal* by Ahmad *et al*.[@ehaa387-B1]

*Innovative investigation*: This study treads novel ground in delineating the comparative effectiveness of each mode of treatment, with focus on prognosis/mortality of the patient post-treatment. Nevertheless, there are some aspects of the meta-analysis that we would like to require addressing.

*Publication bias*: Ahmad *et al*. used PRISMA guidelines for conducting of the analysis, which requires that meta-analysis studies also conduct publication bias assessment.[@ehaa387-B2] Therefore, we would like to recommend publication bias analysis using Egger's bias indicator test.[@ehaa387-B3]

*Variance of true effect size*: We recommend the use of the Tau[@ehaa387-B2] parameter, in addition to the *I*^2^ parameter for the assessment of between study heterogeneity, in order to present a more robust analysis (*Table [1](#ehaa387-T1){ref-type="table"}*).

###### 

Heterogeneity and hypothesis testing of the included studies

  Subgroups                   Heterogeneity   HR      95% CI  HR     95% CI   Fixed effects model   Random effects model                                                   
  --------------------------- --------------- ------ -------- ------ -------- --------------------- ---------------------- ------ ------ ------- ------ --- ------- ------ ---
  Risk of death               7.12            0.13    43.89   1.08   0.90     1.30                  1.03                   0.78   1.35   0.87     0.38  5   0.22     0.83  5
  Risk of cardiac death       3.80            0.28    21.07   1.03   0.78     1.35                  1.01                   0.74   1.39   0.22     0.83  4   0.10     0.92  4
  Risk of stroke              9.2             0.06    56.51   0.75   0.52     1.08                  0.73                   0.36   1.47   −1.53    0.13  5   −0.87    0.37  5
  Risk of MI                  1.45            0.69      0     1.24   0.95     1.62                  1.25                   0.95   1.63   1.61     0.10  4   1.61     0.11  4
  Risk of revascularization   0.72            0.95      0     1.88   1.58     2.25                  1.89                   1.58   2.25   7.09      0    5   7.09      0    5

*Pooled effect size*: In addition, we observe that the study conducted used relative risk as the effect size metric for meta-analysis. However, while combining randomized controlled trials in a meta-analysis, the standard mean difference may be a more appropriate effect size metric to represent the pooled data.[@ehaa387-B4]

*Sample size*: The lack of sufficient number of studies is also an issue, as the meta-analysis conducted here only uses a total of five studies, which is not sufficient to provide a result of sufficient power to be used in clinical decision-making. A limitation that requires highlighting.

*Survival endpoints*: We would also like the authors to describe their reasoning behind comparison of studies with different endpoints, as the studies are split between a 5-year follow-up, and a 1-year follow-up, and comparing studies with variable endpoints may introduce heterogeneity into the study.[@ehaa387-B1]

*Statistical significance or estimated effect size*: It is also recommended that the results of the study be described purely in terms of the effect size metric in the meta-analysis, and not using 'statistical significance', as it has shown to be limited in describing statistical results.[@ehaa387-B5]

It also worth noting that as this study is a literature based meta-analysis, the results may guide clinical decision making, but it cannot present any recommendations for treatment.
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